CompletedNot Applicable

COVID-19 and ICU-acquired MDR Bacteria

France368 participantsStarted 2020-05-18

Plain-language summary

This multicenter before-after study aimed to determine the impact of infection related to SARS-CoV-2 on the incidence of ICU-acquired multidrug resistant (MDR) bacteria.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Expected ICU stay \> 48 hours * Rectal and nasal BMR screening performed \< 48 hours after admission to ICU Exclusion Criteria: * Patients aged \< 18 years Refusal to take part in the study ICU-stay \< 48 hours At least a second rectal and nasal BMR screening was not performed prior to ICU discharge (a posteriori exclusion criterion).

What they're measuring

Cumulative incidence of ICU-acquired colonization related multidrug resistant bacteria

Timeframe: from D3 until day 28 after ICU admission

Trial details

NCT IDNCT04378842

SponsorUniversity Hospital, Lille

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-07-26

View on ClinicalTrials.gov More Sars-CoV2 trials